Adagene Inc. Stock Price, News & Analysis

Adagene Inc. (Nasdaq: ADAG) has reported promising interim results from its ongoing phase 1b/2 trials for ADG126, a masked anti-CTLA-4 SAFEbody. The trials, which presented findings at the AACR Annual Meeting, highlight a combination therapy with anti-PD-1 treatments showing tumor shrinkage and stable disease in previously untreated patients. Specifically, 22.6% of patients experienced Grade 3 treatment-related adverse events (TRAEs), indicating a best-in-class safety profile. Notably, clinical responses were observed with three partial responses and significant tumor shrinkage in patients with metastatic colorectal cancer. Additionally, ongoing dose expansion studies aim to further evaluate disease control rates and overall survival. Partnerships with Roche are also set to explore ADG126 in combination with other therapies for advanced HCC.

Adagene Inc. (Nasdaq: ADAG) reported its financial results for 2022, highlighting a cash balance of US$143.8 million to support operations through 2025. The company presented favorable clinical data for its anti-CTLA-4 programs, including ADG116 and ADG126, demonstrating best-in-class safety and efficacy profiles. Collaborations with Roche and Sanofi offer a potential multi-billion dollar non-dilutive funding opportunity. However, Adagene experienced a net loss of US$80.0 million, reflecting increased R&D expenses to advance its pipeline. Positive trial results and strategic collaborations aim to enhance shareholder value.

Adagene Inc. (Nasdaq: ADAG) announced significant developments in its clinical trials during the AACR Annual Meeting 2023. Key highlights include the presentation of ADG126 phase 1b/2 trial results, showcasing its effectiveness in combination with anti-PD-1 therapies. Findings indicate compelling safety and confirmed clinical responses, with particular attention to late-onset toxicity when combined with pembrolizumab. Additionally, details on ADG153, a new masked anti-CD47 IgG1 SAFEbody, reveal strong anti-tumor activity in preclinical models. Presentations are scheduled from April 14-19, 2023, in Orlando, Florida.

Adagene Inc. (Nasdaq: ADAG) announces the appointment of Professor Aurélien Marabelle to its Scientific and Strategic Advisory Board. Professor Marabelle, an expert in oncology and immunology, has significant experience in early-phase clinical trials of cancer immunotherapies. His research focuses on targeting tumor-specific regulatory T-cells (Tregs) using Adagene’s SAFEbody technology for effective systemic delivery of anti-CTLA-4 therapies. This strategic addition is expected to enhance Adagene’s understanding of tumor-specific Treg depletion, further strengthening its pipeline of innovative immunotherapy programs.

Adagene Inc. (Nasdaq: ADAG) announced positive data for its anti-CTLA-4 SAFEbody, ADG126, in combination with anti-PD-1 therapy for advanced solid tumors. In a study of 14 patients, no dose-limiting toxicities were observed with ADG126, demonstrating a compelling safety profile. The trial also showed confirmed partial responses and ongoing tumor shrinkage in multiple tumor types, including resistant variants. The company is expanding dose optimization strategies in line with the FDA's Project Optimus initiative, looking to enhance therapeutic efficacy while minimizing toxicity.

Adagene Inc. (Nasdaq: ADAG) announces that CEO Peter Luo will present a corporate update at the Biotech Showcase™ 2023 on January 9-11 in San Francisco, coinciding with the J.P. Morgan Healthcare Conference. The presentation is scheduled for 11:30 a.m. Pacific time at the Hilton San Francisco, Union Square. A live webcast will be available on Adagene's investor website, with a replay accessible for 30 days. Adagene focuses on developing novel antibody-based cancer immunotherapies using advanced technologies like its Dynamic Precision Library.

Adagene Inc. (Nasdaq: ADAG) announced a collaboration with Roche to evaluate its ADG126 in combination with Roche's atezolizumab and bevacizumab for treating advanced hepatocellular carcinoma (HCC). The trial will be a randomized phase 1b/2 study, initially involving 60 patients. Adagene retains global rights for ADG126. This collaboration seeks to improve treatment efficacy in a disease with a high mortality rate, leveraging Adagene's SAFEbody technology to enhance safety and efficacy while addressing the challenges of combining therapies.

Adagene Inc. (Nasdaq: ADAG) announced interim phase 1b/2 clinical data for its anti-CTLA-4 antibody ADG116, showcased at the Society for Immunotherapy of Cancer Annual Meeting. Significant findings include: two partial responses in Kaposi’s sarcoma and renal cell carcinoma as monotherapy, and a confirmed durable complete response in head and neck cancer when combined with toripalimab. Additionally, ADG116 demonstrated a potent activity in microsatellite-stable colorectal cancer, with no dose-limiting toxicities reported. The overall disease control rate reached 33% across monotherapy dose levels.

Adagene Inc. (Nasdaq: ADAG) has announced the presentation of clinical data for its anti-CTLA-4 antibody candidate, ADG116, at the SITC Annual Meeting on November 10, 2022. The phase 1b/2 studies demonstrate a differentiated safety profile across dosing levels, including monotherapy and combination with anti-PD-1 therapies. Notably, the data highlights anti-tumor activity in both warm and cold tumors, as well as objective responses in tumor types lacking approved anti-CTLA-4 treatments. The findings will be available on Adagene's website post-presentation.